A Phase 3 interventional study of Risankizumab and Autoinjector in Psoriasis, sponsored by AbbVie. Completed at 26 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-11.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing risankizumab in Psoriasis — 1 open to participants now, 2 under way, 1 of them phase 3. risankizumab · Psoriasis.
Among the 30 studies testing risankizumab in Psoriasis, this one is the 22nd largest by enrollment, is one of 3 that started in 2019, is one of 17 in phase 3, and was the 16th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →1 of the 30 studies testing risankizumab in Psoriasis is open now, in 1 country. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
risankizumab: first FDA approval 2019 (SKYRIZI), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 108 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 162 across the 30 interventional studies. Of the 27 that completed or were terminated, 19 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 30 have an industry lead sponsor. The 7 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
79 studies in Psoriasis by AbbVie: 2 open now, 6 under way, 1 of them phase 3. Of 71 finished, 42 (59%) have results posted.
Among the 79 studies in Psoriasis by AbbVie, this one is the 35th largest by enrollment of the 48 interventional ones that give a count, is one of 6 that started in 2019, is one of 31 in phase 3, and was the 56th registered.
AbbVie’s Psoriasis studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 30 studies testing risankizumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 79 in Psoriasis:
This tab as a report to print or save as PDF → With an account.
The objectives of this study were to evaluate the usability of the combination product of risankizumab in an autoinjector (AI), as well as to evaluate the efficacy, safety, and tolerability of risankizumab administered by AI for the treatment of adult participants with moderate to severe plaque psoriasis.
This was a Phase 3 multicenter, single-arm, open-label study that evaluated usability and efficacy of the risankizumab-AI combination product. The study included a 30-day screening period with study visits at Weeks 0, 4, 16, 28, and 40 with a subsequent follow-up telephone call at approximately 20 weeks after the last dose of study drug (Week 48). Study drug dosing consisted of 4 self-administered doses given subcutaneously on Weeks 0, 4, 16, and 28. Dosing on Weeks 4 and 16 was self-administered at home.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participant meets following disease activity criteria:
Exclusion Criteria:
Risankizumab solution (150 mg/mL) for injection; self-administered subcutaneously via a pre-filled autoinjector at Weeks 0, 4, 16, and 28
Drug: Risankizumab · Device: Autoinjector
Risankizumab to be injected subcutaneously (SC)
Also known as: ABBV-066, BI 655066
Single dose pre-filled autoinjector containing risankizumab for SC injection
Percentage of Participants With an Observer Rating of Successful Participant Self-administration
Successful participant self-administration is defined as successfully completed the sequence of 4 critical steps in the Instructions for Use (IFU) without errors to administer study drug via the autoinjector. The steps are "chose an appropriate injection site"; "removed cap from autoinjector"; "activated the injection"; and "performed a complete injection".
Time frame: Day 1 and Week 28
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 90 at Week 16
The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI 90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at Week 16) / PASI score at Baseline \* 100.
Time frame: At Week 16
Percentage of Participants Achieving Static Physician Global Assessment (sPGA) of Clear or Almost Clear at Week 16
The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema, induration, and scaling of psoriatic lesions are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean \>0, \<1.5; Mild (2) = mean ≥1.5, \<2.5; Moderate (3) = mean ≥2.5, \<3.5; and Severe (4) = mean ≥3.5.
Time frame: At Week 16
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 100 at Week 16
The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI 100 is defined as a 100% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at Week 16) / PASI score at Baseline \* 100.
Time frame: At Week 16
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 at Week 16
The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI 75 is defined as at least a 75% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at Week 16) / PASI score at Baseline \* 100.
Time frame: At Week 16
Percentage of Participants Who Had No Potential Hazards as Measured by an Observer
Potential hazards are measured by an observer on the possible use-related hazards checklist for self-administration with the autoinjector. Hazards include injection at incorrect site; administration delayed because of cap removal difficulties; slip hazard during cap disposal attempt; small component swallowed after incorrect disposal of cap; patient received less medication than intended; needle shield did not deploy and resulted in sharps exposure; and pen not discarded properly and resulted in a biohazard for others.
Time frame: Day 1 and Week 28
Participant Rating of Acceptability by the Self-Injection Assessment Questionnaire (SIAQ)
Participants completed the Self-Injection Assessment Questionnaire (SIAQ), an instrument previously validated in those with rheumatoid arthritis, on an electronic patient-report outcome (ePRO) device. The POST module includes four principal causal domains: feelings about injections, self-confidence, pain and reaction during or after the injection, and ease of use, plus two additional domains on satisfaction with self-injection and self-image. Participants rate each item of the SIAQ 20 to 40 minutes following injections, and the ratings are transformed to scores ranging from 0 (worst experience) to 10 (best experience). The domain score is the mean of the item scores included in the domain. Higher domain scores indicate wider acceptability by subjects to use the autoinjector.
Time frame: Day 1, Week 4, Week 16, Week 28
Percent Change From Baseline in Psoriasis Area Severity Index (PASI) Score up to Week 16
The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked.The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. Negative values indicate an improvement from baseline.
Time frame: Baseline, Week 4, and Week 16
| Milestone | Risankizumab |
|---|---|
| Started | 108 |
| Completed | 96 |
| Not completed | 12 |
| Withdrew: Adverse event | 1 |
| Withdrew: Lost to follow-up | 8 |
| Withdrew: Lack of efficacy | 1 |
| Withdrew: Other, not specified | 2 |
Successful participant self-administration is defined as successfully completed the sequence of 4 critical steps in the Instructions for Use (IFU) without errors to administer study drug via the autoinjector. The steps are "chose an appropriate injection site"; "removed cap from autoinjector"; "activated the injection"; and "performed a complete injection".
| percentage of participants | Risankizumab |
|---|---|
| Day 1 | 100 |
| Week 28 | 100 |
The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI 90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at Week 16) / PASI score at Baseline \* 100.
| percentage of participants | Risankizumab |
|---|---|
| Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 90 at Week 16 | 66.7 (57.8 to 75.6) |
The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema, induration, and scaling of psoriatic lesions are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean \>0, \<1.5; Mild (2) = mean ≥1.5, \<2.5; Moderate (3) = mean ≥2.5, \<3.5; and Severe (4) = mean ≥3.5.
| percentage of participants | Risankizumab |
|---|---|
| Percentage of Participants Achieving Static Physician Global Assessment (sPGA) of Clear or Almost Clear at Week 16 | 81.5 (74.2 to 88.8) |
The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI 100 is defined as a 100% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at Week 16) / PASI score at Baseline \* 100.
| percentage of participants | Risankizumab |
|---|---|
| Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 100 at Week 16 | 46.3 (36.9 to 55.7) |
The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI 75 is defined as at least a 75% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at Week 16) / PASI score at Baseline \* 100.
| percentage of participants | Risankizumab |
|---|---|
| Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 at Week 16 | 84.3 (77.4 to 91.1) |
Potential hazards are measured by an observer on the possible use-related hazards checklist for self-administration with the autoinjector. Hazards include injection at incorrect site; administration delayed because of cap removal difficulties; slip hazard during cap disposal attempt; small component swallowed after incorrect disposal of cap; patient received less medication than intended; needle shield did not deploy and resulted in sharps exposure; and pen not discarded properly and resulted in a biohazard for others.
| percentage of participants | Risankizumab |
|---|---|
| Day 1 | 100 |
| Week 28 | 100 |
Participants completed the Self-Injection Assessment Questionnaire (SIAQ), an instrument previously validated in those with rheumatoid arthritis, on an electronic patient-report outcome (ePRO) device. The POST module includes four principal causal domains: feelings about injections, self-confidence, pain and reaction during or after the injection, and ease of use, plus two additional domains on satisfaction with self-injection and self-image. Participants rate each item of the SIAQ 20 to 40 minutes following injections, and the ratings are transformed to scores ranging from 0 (worst experience) to 10 (best experience). The domain score is the mean of the item scores included in the domain. Higher domain scores indicate wider acceptability by subjects to use the autoinjector.
| units on a scale | Risankizumab |
|---|---|
| Feelings about injections- Day 1 | 8.358 ± 2.3613 |
| Self-confidence- Day 1 | 8.556 ± 2.0646 |
| Satisfaction with self-injection- Day 1 | 9.056 ± 1.0321 |
| Injection-site reactions- Day 1 | 9.817 ± 0.4469 |
| Ease of use- Day 1 | 8.82 ± 1.415 |
| Self-image- Day 1 | 9.53 ± 1.261 |
| Feelings about injections- Week 4 | 8.478 ± 2.0024 |
| Self-confidence- Week 4 | 8.112 ± 2.6313 |
| Satisfaction with self-injection- Week 4 | 9.096 ± 1.1572 |
| Injection-site reactions- Week 4 | 9.700 ± 0.5710 |
| Ease of use- Week 4 | 8.84 ± 1.240 |
| Self-image- Week 4 | 9.16 ± 1.964 |
| Feelings about injections- Week 16 | 8.750 ± 1.8483 |
| Self-confidence- Week 16 | 8.367 ± 2.5921 |
| Satisfaction with self-injection- Week 16 | 9.229 ± 1.1517 |
| Injection-site reactions- Week 16 | 9.763 ± 0.4576 |
| Ease of use- Week 16 | 8.93 ± 1.394 |
| Self-image- Week 16 | 9.28 ± 1.678 |
| Feelings about injections- Week 28 | 8.675 ± 2.0661 |
| Self-confidence- Week 28 | 8.795 ± 2.3034 |
| Satisfaction with self-injection- Week 28 | 9.458 ± 1.0500 |
| Injection-site reactions- Week 28 | 9.725 ± 0.8911 |
| Ease of use- Week 28 | 9.39 ± 0.971 |
| Self-image- Week 28 | 9.34 ± 1.614 |
The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked.The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. Negative values indicate an improvement from baseline.
| percent change from Baseline | Risankizumab |
|---|---|
| Week 4 | -61.57 (-66.502 to -56.636) |
| Week 16 | -89.33 (-92.915 to -85.750) |
Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from the first dose of study drug until 20 weeks after last study drug administration, up to 48 weeks. In addition, serious adverse events and protocol-related nonserious adverse events were collected from the time the participant signed the study-specific informed consent.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Risankizumab | 0/108 (0%) | 6/108 (5.6%) | 12/108 (11.1%) |
| Event | Risankizumab |
|---|---|
| ATRIAL FIBRILLATIONCardiac disorders | 1/108 |
| PYREXIAGeneral disorders | 1/108 |
| APPENDICITISInfections and infestations | 1/108 |
| PYELONEPHRITISInfections and infestations | 1/108 |
| THERMAL BURNInjury, poisoning and procedural complications | 1/108 |
| LUMBAR SPINAL STENOSISMusculoskeletal and connective tissue disorders | 1/108 |
| PROSTATITISReproductive system and breast disorders | 1/108 |
| Event | Risankizumab |
|---|---|
| NASOPHARYNGITISInfections and infestations | 8/108 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 6/108 |
Intent-to-treat (ITT) population: all participants who received at least one dose of study drug
| Age, Continuous(years) | Risankizumab |
|---|---|
| Mean | 49.2 ± 14.32 |
| Sex: Female, Male(Participants) | Risankizumab |
|---|---|
| Female | 42 |
| Male | 66 |
| Race/Ethnicity, Customized(Participants) | Risankizumab |
|---|---|
| White | 95 |
| Black or African American | 5 |
| Asian | 7 |
| American Indian or Alaska Native | 1 |
| Native Hawaiian or other Pacific Islander | 0 |
| Other | 0 |
| Multiple | 0 |
| Missing | 0 |
| Prior Use of Systemic Biologic for Psoriasis(Participants) | Risankizumab |
|---|---|
| 0 | 60 |
| ≥1 | 48 |
| Static Physician Global Assessment (sPGA) Score at Baseline(Participants) | Risankizumab |
|---|---|
| Score of 3 | 88 |
| Score of 4 | 20 |
| Psoriasis Area and Severity Index (PASI) Score at Baseline(units on a scale) | Risankizumab |
|---|---|
| Mean | 19.834 ± 7.2424 |
| Body Surface Area (BSA) Psoriasis Involvement at Baseline(Percentage of body surface area affected) | Risankizumab |
|---|---|
| Mean | 25.471 ± 17.4671 |
| Duration of Plaque Psoriasis(years) | Risankizumab |
|---|---|
| Mean | 16.89 ± 13.095 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
Data sharing details ↗ · www.abbvie.com
Ran from Jun 2019 to primary completion in Apr 2020, 10 months.
Results were first posted in May 2021, 1 year after primary completion.
Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 10 months is below that.
Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Risankizumab